Notice of allowance of Breast Cancer Patent in Japan
DiaGenic has received notice of allowance of the family 3 patent application in Japan ( 2007-514130). The claims allowed cover the use of some important gene sequences in blood sample for detection and monitoring of breast cancer. The patent will be valid until 2025. Family 3 patents have earlier been granted in US and Europe. "The new Japanese patent is an important milestone which strengthens our position in Asia. The company will now have a broad patent protection in Japan, one of the largest economies in the world” said DiaGenic CEO Henrik Lund MD PhD.